Table 3.

Univariate analysis results

	≥Grade 2 radiation pneumonitis OR (range)	P value
Age at RTa	1.04 (0.94–1.28)	0.14
Sex
Female (ref.)	2.16 (0.28–5.54E44)	0.24
Male
Smoking history
Never (ref.)	3.27 (0.00–4.48E40)	0.12
Former
Current
Concurrent systemic therapy
Yes	1.17 (0.09–5.11E44)	0.51
No
Concurrent systemic corticosteroids
Yes	1.30 (0.08–2.06E44)	0.55
No
Resolution of irAE symptoms
Yes	1.30 (5E-113–2.88E44)	0.55
No
Grade of irAE
Grade 2	1.29 (0.04–7.56)	0.56
Grade 3–4
Time between irAE and RTb	1.00 (1.00–1.01)	0.48
Time between last ICI treatment and RTc	1.00 (1.00–1.01)	0.50
Mean lung dosed	1.49 (1.11–8.11E165)	0.00002

ICI, immune checkpoint inhibitor; irAE, immune-related adverse event; OR, odds ratio; ref, reference; RT, radiotherapy.

^aAge was assessed as a continuous variable.

^bTime between onset of ICI-associated irAE and RT was assessed as a continuous variable.

^cTime between last ICI treatment and RT was assessed as a continuous variable.

^dMean lung dose was assessed as a continuous variable as the equivalent dose in 2 Gy fractions (EQD2) assuming α/β = 3 Gy, which take into consideration dose and fraction size (see Methods).